TCM
TEVA icon

Triarii Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Triarii Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$4.74M Hold
220,000
– – 4.84% 9
2018
Q2 		$5.35M Buy
220,000
+20,000
+10% +$408K 5% 9
2018
Q1 		$3.42M Hold
200,000
– – 3.95% 12
2017
Q4 		$3.79M Buy
+200,000
New +$3.01M 4.12% 12

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Triarii Capital Management's TEVA Position: Q3 2018 in Review

Triarii Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q3 2018 at 220,000 shares worth $4.74M. The position accounts for 4.84% of the portfolio, ranked #9.

Triarii Capital Management first reported a position in TEVA in Q4 2017 and has held it in 4 quarters since. The position peaked at $5.35M in Q2 2018. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • Triarii Capital Management held 220,000 shares of Teva Pharmaceuticals worth $4.74M as of Q3 2018.
  • Triarii Capital Management left its Teva Pharmaceuticals share count unchanged in Q3 2018.
  • Teva Pharmaceuticals made up 4.84% of Triarii Capital Management's portfolio in Q3 2018, its #9 holding.
  • Triarii Capital Management first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • Triarii Capital Management's Teva Pharmaceuticals position peaked at $5.35M in Q2 2018.
  • 557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Triarii Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.